Emergent Virology, LLC
- UEI
- GMUKDDR5TMU7
- CAGE
- 6DDN6
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- emergentbiosolutions.com
- Founded
- 1998
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A broad spectrum, host based antiviral drug for biodefence | National Institute of Allergy and Infectious Diseases (NIH) | $32,649,682 |
Quick answers
Is Emergent Virology, LLC registered in SAM.gov?
Emergent Virology, LLC's SAM.gov registration expired on July 31, 2022.
What is Emergent Virology, LLC's most recent federal award?
Emergent Virology, LLC's most recent federal contract award is A broad spectrum, host based antiviral drug for biodefence (HHSN272201100030C), from National Institute of Allergy and Infectious Diseases (NIH), on September 27, 2011.
On GovTribe
See Emergent Virology, LLC's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors